Polyrizon (PLRZ) Stock Price, News & Analysis

Company Overview

Polyrizon Ltd. is a biotechnology company developing nasal and respiratory-care products based on proprietary hydrogel technology. Its platform is designed to create a physical barrier on mucosal surfaces, potentially helping limit exposure to allergens, pollutants, and other airborne particles.

The company’s product candidates are focused primarily on intranasal applications, including solutions intended for allergic rhinitis and other upper-respiratory conditions. Polyrizon has described its technology as mucoadhesive, meaning that the hydrogels are designed to remain on nasal surfaces for an extended period while supporting localized protection.

Polyrizon is headquartered in Israel and is advancing its platform through product development and clinical or regulatory activities. The company’s programs and commercialization plans remain subject to development, testing, and applicable regulatory approvals.

Key Stats

• Today's Range: $8.76 to $9.14
• 50-Day Range: $8.87 to $14.51
• 52-Week Range: $2.88 to $18.20
• Volume: 6,404 shs
• Average Volume: 25,738 shs
• Market Capitalization: $21.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Polyrizon Stock Analysis - MarketRank™

Polyrizon scored higher than 18% of companies evaluated by MarketBeat, and ranked 800th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Polyrizon has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Polyrizon has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Polyrizon has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.09% of the float of Polyrizon has been sold short.

Short Interest Ratio / Days to Cover

Polyrizon has a short interest ratio ("days to cover") of 1.84, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Polyrizon has recently decreased by 8.47%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Polyrizon does not currently pay a dividend.

Dividend Growth

Polyrizon does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.79

News Sentiment

Polyrizon has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Polyrizon this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for PLRZ on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Polyrizon insiders have not sold or bought any company stock.

Percentage Held by Institutions

Polyrizon has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 9/28/2026
• Today: 10/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PLRZ
• Previous Symbol: NASDAQ:PLRZ
• CIK: 1893645
• Web: www.polyrizon-biotech.com
• Phone: 972-55-433-5665
• Fax: N/A
• Employees: 1
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 36.37
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.05 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 2,430,000
• Free Float: N/A
• Market Cap: $21.99 million
• Optionable: N/A
• Beta: -1.20